Zimmer Biomet (ZBH) stock fell by 1.07% following an announcement of a definitive agreement to acquire Monogram Technologies, which aims to improve orthopedic surgery through AI-driven robotics, potentially signaling investor concerns about integration and market competition.

Zimmer Biomet (ZBH) stock fell by 1

Zimmer Biomet (ZBH) stock declined by 1.61% after Allianz Asset Management reduced its position in the company by 25.7% and multiple analysts lowered their price targets, reflecting concerns over the company's valuation amid mixed recent performance.

Zimmer Biomet (ZBH) stock declined by 1

Zimmer Biomet (ZBH) stock rose by 0.7% following a combination of strong quarterly earnings that surpassed analyst expectations, a recent dividend declaration, and continued interest from institutional investors despite some stake reductions.

Zimmer Biomet (ZBH) stock rose by 0

Zimmer Biomet (ZBH) stock rose 0.7% due to significant institutional buying, despite some recent decreases in analysts' price targets and insider selling, indicating strong interest from institutional investors.

Zimmer Biomet (ZBH) stock rose 0

ZimVie Inc. (Nasdaq: ZIMV) announced it will be acquired for $19.00 per share by an affiliate of ARCHIMED, which led to a 0.7% increase in Zimmer Biomet (ZBH) stock as investors reacted positively to the acquisition news.

ZimVie Inc

Zimmer Biomet Holdings, Inc. (ZBH) shares are experiencing downward pressure, reflected in a -0.47% decline, due to recent downgrades and target price reductions from several analysts, shifting the average rating to "Hold."

Zimmer Biomet Holdings, Inc

Zimmer Biomet (ZBH) stock decreased by 0.47% following several analysts reducing their price targets for the company, which reflects a negative sentiment in the market for the stock.

Zimmer Biomet (ZBH) stock decreased by 0

Zimmer Biomet (ZBH) stock rose by 1.52% to $97.99, reflecting a 5.16% increase over the last month, likely due to positive market sentiment or upcoming developments, despite a 12.03% decline over the past year.

Zimmer Biomet (ZBH) stock rose by 1

Zimmer Biomet (ZBH) stock rose 4.24% after the company announced a definitive agreement to acquire Monogram Technologies for around $177 million, enhancing its capabilities in surgical robotics and navigation, which investors believe will drive long-term growth and innovation in the orthopedic market.

Zimmer Biomet (ZBH) stock rose 4

Zimmer Biomet (ZBH) stock rose by 4.24% last night, attributed to both an increase in hedge fund investments and strong quarterly earnings that exceeded analyst expectations.

Zimmer Biomet (ZBH) stock rose by 4

Zimmer Biomet (ZBH) stock rose by 0.72% following an upgrade from Roth Capital from a “neutral” to a “buy” rating, indicating a potential upside based on a target price of $135.00.

Zimmer Biomet (ZBH) stock rose 0.2% recently, likely due to the announcement of its acquisition of Monogram Technologies Inc., which includes attractive contingent value rights for Monogram shareholders that may signal future growth prospects for ZBH.

Zimmer Biomet (ZBH) stock rose by 0.2% due in part to significant hedge fund interest, with several institutions increasing their stakes in the company, alongside a positive quarterly earnings report that exceeded analyst expectations.

Zimmer Biomet Holdings, Inc. (ZBH) stock rose by 0.2% following the announcement of a strategic acquisition of Monogram Technologies, aimed at enhancing its robotics and enabling technologies offerings, despite a neutral outlook from analysts due to concerns about surgeon adoption of fully automated systems. 

The stock's increase can be attributed to positive investor sentiment around the potential benefits of this acquisition in bolstering the company's position in the robotics market.

Zimmer Biomet (ZBH) stock saw a 0.2% increase, reflecting its status as an undervalued medical device company, despite a neutral "Hold" rating from Needham analyst Michael Matson. The stock's rise may be attributed to its perceived undervaluation in the market.

Zimmer Biomet (ZBH) stock saw a 0

Zimmer Biomet (ZBH) stock rose by 0.2% due to increased institutional investment, as several firms, including Allworth Financial LP, boosted their stakes in the company, reflecting growing confidence in its performance following a positive earnings report that surpassed expectations.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) saw a 0.18% increase in its stock price due to positive outlooks from the Oakmark Equity and Income Fund regarding its potential for growth in the orthopedic market, driven by long-term trends like an aging population and operational improvements from new management.

Zimmer Biomet (ZBH) stock increased by 0.07% following the announcement of its acquisition of Monogram Technologies for $177 million, which is expected to enhance its portfolio in orthopedic robotics and contribute to revenue growth starting in 2027.

Zimmer Biomet (ZBH) stock increased by 0

Zimmer Biomet (ZBH) stock saw a slight increase of 0.07% due to institutional investors adjusting their holdings positively, alongside the company's earnings beating expectations and the announcement of a quarterly dividend, indicating stable financial performance.

Zimmer Biomet (ZBH) stock saw a slight increase of 0

Zimmer Biomet (ZBH) stock rose 0.07% due to its proposed acquisition of Monogram Technologies Inc., which includes an upfront cash payment as well as contingent value rights for shareholders tied to future milestones.

Zimmer Biomet (ZBH) stock rose by 0.07% following its announcement to acquire Monogram Technologies for $4.04 per share, providing potential value to shareholders through contingent rights contingent on future milestones.

Zimmer Biomet (ZBH) stock rose by 0.07% following its acquisition of Monogram Technologies Inc. for $4.04 per share, along with additional contingent value rights, which reflects positive market sentiment towards the strategic expansion and potential growth from the deal.

Zimmer Biomet (ZBH) stock fell by -1.43% after Evercore ISI lowered its price target from $102.00 to $96.00, reflecting a general trend of reduced price targets from several brokerages, which contributed to the negative market sentiment surrounding the stock.

Zimmer Biomet (ZBH) stock fell by -1

Zimmer Biomet (ZBH) stock rose by 1.85% due to a combination of positive quarterly earnings that exceeded estimates and ongoing interest from institutional investors, despite a significant reduction in holdings by the Teacher Retirement System of Texas.

Zimmer Biomet (ZBH) stock increased by 0.97% due to institutional investors like D.A. Davidson & CO. boosting their stakes in the company, suggesting growing confidence in its market performance, along with positive quarterly earnings that exceeded analyst expectations.

Zimmer Biomet (ZBH) stock increased by 0.18% following a significant raise in institutional investments, particularly by Mirae Asset Global Investments Co. Ltd., which boosted its stake by 12.6%, indicating positive investor sentiment and confidence in the company's performance.

Zimmer Biomet (ZBH) stock rose by 0.18% following a combination of institutional investor activity, including a slight reduction in KBC Group NV's holdings and increases from other hedge funds, positive earnings results that exceeded analysts' expectations, and a recently announced dividend.

Zimmer Biomet (ZBH) stock fell by 0.6% due to a combination of insider selling and mixed analyst sentiments following a recent earnings report that showed modest revenue growth but lower earnings per share compared to the previous year.

Zimmer Biomet (ZBH) stock fell by 0

Zimmer Biomet (ZBH) stock fell by 0.6% as it faces downgraded price targets from multiple equity analysts, with concerns affecting investor sentiment despite reporting a slight earnings beat. 

The stock's decline could be attributed to recent downward revisions by analysts on its price targets, indicating market caution regarding the company's future performance.

Zimmer Biomet (ZBH) stock fell by 0.6% last night as analysts decreased their price targets and ratings amid mixed performance and insider selling activity.

Zimmer Biomet (ZBH) stock experienced a decrease of -0.31% due to a mix of institutional ownership changes, recent downgrades in price targets from multiple brokerages, and insider selling, indicating potential concerns among investors.

Zimmer Biomet (ZBH) stock experienced a decrease of -0

Zimmer Biomet (ZBH) stock decreased by 0.31% following a 29.5% reduction in Continuum Advisory LLC's stake and recent downward adjustments in price targets by several research analysts, indicating potential investor concerns about the company's future performance.

Zimmer Biomet Holdings, Inc. (ZBH) saw a slight increase of 0.49% in its stock price, likely due to positive earnings results that exceeded analyst expectations and the company's dividend announcement.

Zimmer Biomet (ZBH) stock rose by 0.49% likely due to strong quarterly earnings that exceeded estimates and the announcement of a forthcoming dividend payment, alongside increased investor interest from institutional trading activities.

Zimmer Biomet Holdings, Inc. (ZBH) saw its stock increase by 0.31% as institutional investments and strategic changes in holdings, particularly from significant entities like the State of Alaska Department of Revenue and Franklin Resources, contributed to positive market sentiment.

Zimmer Biomet (ZBH) stock increased by 0.31% after notable institutional investments, including a 20% stake increase by Kingswood Wealth Advisors and significant purchases by other hedge funds, reflecting positive sentiment and confidence in the company's performance despite a recent insider sale.

ZBH

Latest News & Analysis